Drug Trial Radar · NCT04133636
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
208
Actual
Start
Nov 7, 2019
Primary completion
Feb 26, 2027
Study completion Aug 25, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 21, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Conditions
- Multiple Myeloma
Interventions
JNJ-68284528Drug
Participants in Cohorts A,B,C, D, E, F and Cohort G (for US sites only) will receive JNJ-68284528 intravenously.
LenalidomideDrug
Some participants in Cohort D and all participants in Cohorts E and Cohort G (for US sites only) will also receive lenalidomide capsules orally.
DaratumumabDrug
Participants in Cohorts E and Cohort G (for US sites only) will also receive daratumumab subcutaneous (SC) injection.
BortezomibDrug
Participants in Cohorts E will also receive bortezomib subcutaneously.
DexamethasoneDrug
Participants in Cohorts E and Cohort G (for US sites only) will also receive dexamethasone orally or intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)Time frame: At least 1 year after JNJ-68284528 infusion on Day 1
- For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)Time frame: At least 1 year after JNJ-68284528 infusion on Day 1
Locations
47 sites in 8 countries. Site status is shown where the registry gives one.
University Of California San Diego
San Diego, California
University of California San Francisco
San Francisco, California
Yale University School Of Medicine
New Haven, Connecticut
Moffitt Cancer Center
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Cancer Center
Westwood, Kansas
Norton Cancer Institute
Louisville, Kentucky
Dana Farber Cancer Institute
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School Of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Mount Sinai Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Levine Cancer Institute, Carolinas HealthCare System
Charlotte, North Carolina
Cleveland Clinic
Cleveland, Ohio
Oregon Health And Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
University of Utah
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
CHRU de Lille Hopital Claude Huriez
Lille, France
C.H.U. Hotel Dieu - France
Nantes, France
Hopital Saint Louis
Paris, France
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany
Universitatsklinikum Wurzburg
Würzburg, Germany
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.